SYK vs. BSX, BDX, DXCM, RMD, ELV, SNY, VRTX, MDT, REGN, and ISRG
Should you be buying Stryker stock or one of its competitors? The main competitors of Stryker include Boston Scientific (BSX), Becton, Dickinson and Company (BDX), DexCom (DXCM), ResMed (RMD), Elevance Health (ELV), Sanofi (SNY), Vertex Pharmaceuticals (VRTX), Medtronic (MDT), Regeneron Pharmaceuticals (REGN), and Intuitive Surgical (ISRG). These companies are all part of the "medical" sector.
Stryker (NYSE:SYK) and Boston Scientific (NYSE:BSX) are both large-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, community ranking, dividends, profitability, earnings, valuation and media sentiment.
Stryker has a beta of 0.91, suggesting that its stock price is 9% less volatile than the S&P 500. Comparatively, Boston Scientific has a beta of 0.77, suggesting that its stock price is 23% less volatile than the S&P 500.
Stryker currently has a consensus target price of $370.50, indicating a potential upside of 9.72%. Boston Scientific has a consensus target price of $75.41, indicating a potential upside of 0.40%. Given Stryker's higher possible upside, equities research analysts clearly believe Stryker is more favorable than Boston Scientific.
77.1% of Stryker shares are owned by institutional investors. Comparatively, 89.1% of Boston Scientific shares are owned by institutional investors. 5.5% of Stryker shares are owned by company insiders. Comparatively, 0.5% of Boston Scientific shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
In the previous week, Stryker and Stryker both had 21 articles in the media. Boston Scientific's average media sentiment score of 0.91 beat Stryker's score of 0.55 indicating that Boston Scientific is being referred to more favorably in the news media.
Stryker has higher revenue and earnings than Boston Scientific. Stryker is trading at a lower price-to-earnings ratio than Boston Scientific, indicating that it is currently the more affordable of the two stocks.
Stryker has a net margin of 16.03% compared to Boston Scientific's net margin of 12.06%. Stryker's return on equity of 23.05% beat Boston Scientific's return on equity.
Boston Scientific received 110 more outperform votes than Stryker when rated by MarketBeat users. Likewise, 69.40% of users gave Boston Scientific an outperform vote while only 64.54% of users gave Stryker an outperform vote.
Summary
Stryker and Boston Scientific tied by winning 9 of the 18 factors compared between the two stocks.
Get Stryker News Delivered to You Automatically
Sign up to receive the latest news and ratings for SYK and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SYK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
